Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT01336738. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-04991532 And Sitagliptin In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.
Study identification
- NCT ID
- NCT01336738
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 266 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- 150 mg PF-04991532 Drug
- 450 mg PF-04991532 Drug
- 750 mg PF-04991532 Drug
- Sitagliptin 100 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2011 (Type not available)
- Primary completion
- Mar 2012 (Actual)
- Completion
- Mar 2012 (Actual)
- Last update posted
- Aug 6, 2013
2011 – 2012
United States locations
- U.S. sites
- 28
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Jonesboro | Arkansas | 72401 | — |
| Pfizer Investigational Site | Jonesboro | Arkansas | 72404 | — |
| Pfizer Investigational Site | Los Angeles | California | 90057 | — |
| Pfizer Investigational Site | Palm Springs | California | 92262 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32216 | — |
| Pfizer Investigational Site | Melbourne | Florida | 32901 | — |
| Pfizer Investigational Site | West Palm Beach | Florida | 33401 | — |
| Pfizer Investigational Site | Conyers | Georgia | 30094 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60607 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40213 | — |
| Pfizer Investigational Site | Fall River | Massachusetts | 02720 | — |
| Pfizer Investigational Site | Brooklyn | New York | 11230 | — |
| Pfizer Investigational Site | Cary | North Carolina | 27518 | — |
| Pfizer Investigational Site | Wilmington | North Carolina | 28401 | — |
| Pfizer Investigational Site | Columbus | Ohio | 43213 | — |
| Pfizer Investigational Site | East Providence | Rhode Island | 02914 | — |
| Pfizer Investigational Site | East Providence | Rhode Island | 02915 | — |
| Pfizer Investigational Site | Mt. Pleasant | South Carolina | 29464 | — |
| Pfizer Investigational Site | Bristol | Tennessee | 37620 | — |
| Pfizer Investigational Site | Kingsport | Tennessee | 37660 | — |
| Pfizer Investigational Site | Dallas | Texas | 75230 | — |
| Pfizer Investigational Site | Houston | Texas | 77036 | — |
| Pfizer Investigational Site | Houston | Texas | 77074 | — |
| Pfizer Investigational Site | Houston | Texas | 77081 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Charlottesville | Virginia | 22911 | — |
| Pfizer Investigational Site | Kenosha | Wisconsin | 53142 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01336738, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2013 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01336738 live on ClinicalTrials.gov.